A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis

New England Journal of Medicine

Volumn 350, Issue 2, 2004, Pages 125-133

  Raghu, Ganesh ^a   Brown, Kevin K ^b   Bradford, Williamson Z ^c   Starko, Karen ^c   Noble, Paul W ^d   Schwartz, David A ^e   King Jr , Talmadge E ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c InterMune Inc   (United States)

^d YALE UNIVERSITY   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GAMMA INTERFERON; GAMMA1B INTERFERON; IBUPROFEN; PARACETAMOL; PLACEBO; PREDNISONE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DYSPNEA; EAR INFECTION; FATIGUE; FEMALE; FEVER; FIBROSING ALVEOLITIS; FLU LIKE SYNDROME; FOLLOW UP; GAS EXCHANGE; HEADACHE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; LARYNGITIS; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MORTALITY; MULTICENTER STUDY; MYALGIA; NAUSEA; NOSE CONGESTION; OTITIS MEDIA; PAIN; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RIGOR; SIDE EFFECT; SINUSITIS; STATISTICAL SIGNIFICANCE; SURVIVAL; THORAX PAIN; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING;

DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA, RECOMBINANT; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; RESPIRATORY TRACT INFECTIONS; RISK; TREATMENT FAILURE;

EID: 0345824715     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa030511     Document Type: Article

References (34)

1. Schwartz DA, Helmers RA, Galvin JK, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994;149:450-4.
2. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
3. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000;161:1172-8.
4. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
5. Johnson MA, Kwan S, Snell NJC, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989;44:280-8.
6. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-6.
7. van Oortegem K, Wallaert B, Marquette CH, et al. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:1950-7.
8. Selman M, Carrillo G, Salas J, et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998;114:507-12.
9. Flaherty KR, Toews GB, Lynch JP III, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001;110:278-82.
10. Billiau A, Vanderbroeck K. IFN γ. In: Oppenheim JJ, Feldmann M, eds. Cytokine reference: a compendium of cytokines and other mediators of host defense. London: Academic Press, 2001:641-88.
11. Narayanan AS, Whithey J, Souza A, Paghu G. Effect of γ-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992;101:1326-31.
12. Clark JG, Dedon TF, Wayner EA, Carter WG. Effects of interferon-γ on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J Clin Invest 1989;83:1505-11.
13. Okada T, Sugie I, Aisaka K. Effects of γ-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res 1993;12:87-91.
14. 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991;88:6642-6.
15. Kuroki S, Ohta A, Sueoka N, Katoh O, Yamada H, Yamaguchi M. Determination of various cytokines and type III procollagen aminopeptide levels in bronchoalveolar lavage fluid of the patients with pulmonary fibrosis: inverse correlation between type III procollagen aminopeptide and interferon-γ in progressive patients. Br J Rheumatol 1995;34:31-6.
16. Keane MP, Arenberg DA, Lynch JP III, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997;159:1437-43.
17. Coker RK, Laurent GJ. Pulmonary fibrosis: cytokines in the balance. Eur Respir J 1998;11:1218-21.
18. Prior C, Haslam PL. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases. Clin Exp Immunol 1992;88:280-7.
19. Wallace WAH, Howie SEM. Immunoreactive interleukin 4 and interferon-γ expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol 1999;187:475-80.
20. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L-H. A preliminary study of long-term treatmentwith interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9. [Erratum, N Engl J Med 2000;342:524.]
21. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L-H. A preliminary study of long-term treatmentwith interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9. [Erratum, N Engl J Med 2000;342:524.]
22. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-γ as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983;158:670-89.
23. Lack G, Gelfand EW. The role of nebulized IFN-γ in the modulation of allergic responses. Adv Exp Med Biol 1996;409:17-23.
24. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988;140:4245-52.
25. Neumann B, Emmanulidis K, Stadler M, Holzmann B. Distinct functions of interferon-γ for chemokine expression in models of acute lung inflammation. Immunology 1998;95:512-21.
26. Duits LA, Ravensbergen B, Rademaker M, Hiemstra P, Nibbering PH. Expression of β-defensin 1 and 2 mRNA by human monocytes, macrophages, and dendritic cells. Immunology 2002;106:517-25.
27. Kahan AB, Amor B, Menkes CJ, Strauch S. Recombinant interferon-γ in the treatment of systemic sclerosis. Am J Med 1989;87:273-7.
28. Hein R, Behr J, Hundgen M, et al. Treatment of systemic sclerosis with γ-interferon. Br J Dermatol 1992;126:496-501.
29. Saez-Royuela F, Porres JC, Moreno A, et al. High doses of recombinant α-interferon or γ-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991;13:327-31.
30. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304. [Erratum, Am J Respir Crit Care Med 2002;166:426.]
31. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304. [Erratum, Am J Respir Crit Care Med 2002;166:426.]
32. King TE Jr, Tooze JA, Schwarz MI, Brown KK, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-81.
33. Chang JA, Curtis JR. Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999;116:1175-82.
34. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.